Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
In brief
The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.
Key facts
- Study ID
- NCT05471843
- Run by
- BeiGene
- People needed
- 125
- Starts
- 2022-09-05
- Expected to finish
- 2027-01-31
- Last updated by the study team
- 2025-09-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia, United States
- Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana, United States
- Des Moines Oncology Research Association — Des Moines, Iowa, United States
- Tulane Cancer Center — New Orleans, Louisiana, United States
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland, United States
- Maryland Oncology Hematology, Pa — Columbia, Maryland, United States
- University of Missouri Hospital, Ellis Fischel Cancer Center — Columbia, Missouri, United States
- Nebraska Cancer Specialists — Grand Island, Nebraska, United States
- Dartmouth Cancer Center — Lebanon, New Hampshire, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- Novant Health Hematology Charlotte — Charlotte, North Carolina, United States
- The University of Texas Md Anderson Cancer Center — Houston, Texas, United States
- Hospital Aleman — Buenos Aires, Argentina
- Az Sint Jan Brugge — Bruges, Belgium
- Universitair Ziekenhuis Gent — Ghent, Belgium
- University Hospitals Leuven — Leuven, Belgium
- AZ DELTA — Roeselare, Belgium
- Hospital Erasto Gaertner — Curitiba, Brazil
- Hospital Mae de Deus — Porto Alegre, Brazil
- Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp — Ribeirão Preto, Brazil
- Oncoclinicas Rio de Janeiro Sa — Rio de Janeiro, Brazil
- Instituto Americas Ensino, Pesquisa E Inovacao — Rio de Janeiro, Brazil
- Hospital Sao Rafael (Rede Dor) — Salvador, Brazil
- Hospital Beneficencia Portuguesa de Sao Paulo — São Paulo, Brazil
- University of Alabama At Birmingham Hospital — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.